Training for Healthcare Providers
Complications of Thalassemia: Disease Effects and Treatment Effects
April 5, 2 to 3 pm Eastern
See details below or click here to view the recording.external icon
Sujit Sheth, MD
Chief, Division of Pediatric
Professor of Clinical Pediatrics
Weill Cornell Medicine
Jennifer Yu, MD
Rady Children’s Hospital
Associate Clinical Professor in Pediatrics
UC San Diego School of Medicine
ACTIVITY NUMBER: WC(SC)4468
Origination Date: October 29, 2021
Expiration Date: October 29, 2023
In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and Cooley’s Anemia Foundation. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 1.0 nursing contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
The thalassemia syndromes are a group of hereditary disorders in the synthesis of hemoglobin that result in varying degrees of anemia. Treatment for severe cases typically includes red blood cell transfusion and iron chelation therapy. Management of thalassemia is complex and may present many challenges to overcome. For example, complications may occur as a result of the underlying disease process as well as the treatment regimen.
In these rounds, Sujit Sheth, MD, will discuss the pathophysiology of complications of thalassemia in both transfused and non-transfused individuals. All of these complications will be discussed in depth, and a monitoring and treatment management plan will be presented.
The target audience for these rounds are physicians, physician assistants, nurses, nurse practitioners, and other healthcare professionals.
The live rounds is presented for 60 minutes, including a pre-test and post-test.
At the conclusion of the rounds, participants will be able to do the following:
- Describe three disease complications in treated and untreated patients with thalassemia.
- Describe three complications of treatment of the disease.
- Describe a rational monitoring and treatment management plan for thalassemia.
For more information, please contact Cynthia Sayers at email@example.com
This project was supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $150,000 with 100 percent funded by CDC/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.